Lannett Company Inc
Change company Symbol lookup
Select an option...
LCI Lannett Company Inc
DOCU DocuSign Inc
IO ION Geophysical Corp
DNRCQ Denbury Resources Inc
MSFT Microsoft Corp
BCRX BioCryst Pharmaceuticals Inc
WMT WALMART STORES INC
ZN Zion Oil and Gas Inc
EBTC Enterprise Bancorp Inc
FSLY Fastly Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Price
Delayed
$6.13
Day's Change
-0.03 (-0.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.34
Day's Low
6.13
Volume
(Heavy Day)

Today's volume of 14,997 shares is on pace to be much greater than LCI's 10-day average volume of 351,339 shares.

14,997

LCI's position in the Pharmaceuticals industry

Industry PeersLCISUPNAMPHASRT

Summary

Company ProfileLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the...
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR...
Go to SUPN summary
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and...
Go to AMPH summary
Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia...
Go to ASRT summary
52-Week Change

VS. INDUSTRY
-9.01%
-18.90%
-2.16%
-51.38%
Market Cap

VS. INDUSTRY
$248.6M
$1.2B
$968.7M
$83.3M
Beta

VS. INDUSTRY
1.7
1.5
1.0
2.1
Dividend Yield

VS. INDUSTRY
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
10.79x
248.81x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$541.7M
$402.3M
$334.0M
$155.9M
Profit Margin

VS. INDUSTRY
-5.77%
28.90%
1.15%
-117.10%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
-21.78%
-0.42%
3.07%
-33.72%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.